Evotec Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Christian Wojczewski

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Christian Wojczewski (52 yo)

less than a year

Mandato

Dr. Christian Wojczewski serves as Chief Executive Officer of Evotec SE since July 01, 2024. He holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe University in Frankfurt am Main....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Laetitia Rouxel	CFO & Member of Management Board	1.6yrs	€890.00k	0.029% CHF 418.5k
Cord Dohrmann	Chief Scientific Officer & Member of Management Board	14.2yrs	€1.48m	0.11% CHF 1.6m
Craig Johnstone	COO & Member of Management Board	5.8yrs	€1.18m	0.011% CHF 163.4k
Christian Wojczewski	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Aurelie Dalbiez	Chief People Officer & Member of Management Board	less than a year	Nessun dato	Nessun dato
Volker Braun	Executive VP and Head of Global Investor Relations & ESG	no data	Nessun dato	Nessun dato
Christian Dargel	EVP Global Head of Legal & Compliance	no data	Nessun dato	Nessun dato
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	no data	Nessun dato	Nessun dato
Ian Hunneyball	Senior Vice President of Programme Management & Clinical Operations	no data	€116.00k	Nessun dato
David Hallet	Executive Vice President	no data	Nessun dato	Nessun dato
Uwe Andag	EVP Head of Metabolic Diseases	no data	Nessun dato	Nessun dato
Christiane Honisch	SVP Head of Diagnostics	no data	Nessun dato	Nessun dato

1.6yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di EVT non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Roland Sackers	Independent Vice Chairperson of the Supervisory Board	5.4yrs	€95.00k	Nessun dato
Iris Loew-Friedrich	Independent Chairperson of the Supervisory Board	10.4yrs	€150.00k	Nessun dato
Duncan McHale	Member of the Supervisory Board	less than a year	Nessun dato	Nessun dato
Camilla Languille	Member of the Supervisory Board	2.4yrs	€60.00k	Nessun dato
Constanze Ulmer-Eilfort	Independent Member of Supervisory Board	3.4yrs	€85.00k	Nessun dato
Wesley Wheeler	Independent Supervisory Board	less than a year	Nessun dato	Nessun dato

2.9yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di EVT non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.

Evotec Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE Announces CEO Transition

Evotec SE, Annual General Meeting, Jun 20, 2023

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Second quarter 2024 earnings released: €0.54 loss per share (vs €0.084 loss in 2Q 2023)

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings released: €0.47 loss per share (vs €0.99 loss in FY 2022)

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Evotec SE Announces CEO Transition

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings released: €0.22 loss per share (vs €0.27 loss in 3Q 2022)

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €0.99 loss per share (vs €1.30 profit in FY 2021)

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Second quarter 2022 earnings released: €0.16 loss per share (vs €0.36 profit in 2Q 2021)

Evotec SE Revises Revenue Guidance for the Full Year 2022

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Evotec SE Confirms Revenue Guidance for 2022

Full year 2021 earnings released: EPS: €1.30 (vs €0.041 in FY 2020)

Full year 2021 earnings released: EPS: €1.30 (vs €0.041 in FY 2020)

Evotec Se Provides Revenue Guidance for 2022

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Third quarter 2021 earnings released: EPS €0.82 (vs €0.009 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.36 (vs €0.065 loss in 2Q 2020)

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Independent Chairman of Supervisory Board Wolfgang Plischke has left the company

First quarter 2021 earnings released: EPS €0.32 (vs €0.11 in 1Q 2020)

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

Evotec SE Launches 'beLAB1407' to Accelerate Translational Research from the UK's Academic Life Science Ecosystem in Collaboration with Bristol Myers Squibb

Full year 2020 earnings released: EPS €0.041 (vs €0.25 in FY 2019)

Evotec SE Provides Earnings Guidance for the Year 2021

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership

Evotec SE Enters into Multi-Year Partnership with the Medical Center Hamburg-Eppendorf

Evotec Appoints Cord Dohrmann to the German Council of Science and Humanities

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation

Evotec SE to Report Q3, 2021 Results on Nov 11, 2021

Evotec SE Receives USD 6 Million Payment from Bristol Myers Squibb Company

Evotec SE Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform

Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology Target

Revenue beats expectations

Third quarter 2020 earnings released: €0.009 loss per share

Evotec SE announced that it expects to receive €249.999996 million in funding from Mubadala Investment Company PJSC, Novo Holdings A/S

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

Earnings released

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente